ArticleNucleic acids research2026
HLTF cooperates with GATA1 to activate transcriptional programs and chromatin remodeling during erythroid development.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Erythropoiesis, the process by which hematopoietic stem cells differentiate into mature red blood cells, is tightly regulated by a complex network of transcriptional and epigenetic mechanisms. While helicase-like transcription factor (HLTF) is known for its roles in transcriptional regulation, chromatin remodeling, and genome stability, its function in erythroid development has remained unexplored. Here, we identify HLTF as a novel regulator of GATA1 and erythropoiesis. HLTF directly binds the GATA1 promoter, enhancing its transcription. In vitro and in vivo assays demonstrated that HLTF promotes erythroid proliferation, survival, and terminal differentiation. HLTF knockout impairs erythropoiesis, effects which are partially rescued by GATA1 overexpression. Multi-omics analyses (RNA-seq, ATAC-seq, and CUT&Tag) reveal that HLTF maintains chromatin accessibility and activates erythroid gene networks. HLTF interacts with GATA1, co-occupies erythroid regulatory regions, and facilitates GATA1 genomic binding. Notably, GATA1 also transcriptionally activates HLTF, forming a positive feedback loop. In erythroid disorders, HLTF is up-regulated in polycythemia vera (PV) and down-regulated in myelodysplastic syndromes (MDS). Knockout of HLTF in PV patient-derived cells suppressed erythroid hyperplasia, reduced chromatin accessibility, and impaired GATA1 binding. Together, these findings reveal HLTF as a transcriptional regulator of GATA1 and a pivotal modulator of erythropoiesis, providing new insights into erythroid lineage control and erythroid-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.